Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.

Détails

Ressource 1Télécharger: 33156338_BIB_75DE24FE756B.pdf (6461.52 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_75DE24FE756B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
Périodique
The Journal of experimental medicine
Auteur(s)
Lanitis E., Rota G., Kosti P., Ronet C., Spill A., Seijo B., Romero P., Dangaj D., Coukos G., Irving M.
ISSN
1540-9538 (Electronic)
ISSN-L
0022-1007
Statut éditorial
Publié
Date de publication
01/02/2021
Peer-reviewed
Oui
Volume
218
Numéro
2
Pages
e20192203
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Limited clinical benefit has been demonstrated for chimeric antigen receptor (CAR) therapy of solid tumors, but coengineering strategies to generate so-called fourth-generation (4G) CAR-T cells are advancing toward overcoming barriers in the tumor microenvironment (TME) for improved responses. In large part due to technical challenges, there are relatively few preclinical CAR therapy studies in immunocompetent, syngeneic tumor-bearing mice. Here, we describe optimized methods for the efficient retroviral transduction and expansion of murine T lymphocytes of a predominantly central memory T cell (TCM cell) phenotype. We present a bicistronic retroviral vector encoding both a tumor vasculature-targeted CAR and murine interleukin-15 (mIL-15), conferring enhanced effector functions, engraftment, tumor control, and TME reprogramming, including NK cell activation and reduced presence of M2 macrophages. The 4G-CAR-T cells coexpressing mIL-15 were further characterized by up-regulation of the antiapoptotic marker Bcl-2 and lower cell-surface expression of the inhibitory receptor PD-1. Overall, this work introduces robust tools for the development and evaluation of 4G-CAR-T cells in immunocompetent mice, an important step toward the acceleration of effective therapies reaching the clinic.
Pubmed
Web of science
Open Access
Oui
Création de la notice
22/11/2020 11:39
Dernière modification de la notice
30/04/2021 6:11
Données d'usage